ADCT earnings: real EPS beat/miss history, analyst consensus Hold, P/E -1.18. Updated 2026-07-23.
ADC Therapeutics (ADCT) Research Hub
ADC Therapeutics (ADCT) trades on NYSE, CH in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.07 USD (-12.30%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.18, market cap 0.15B. This hub links to the full technical, earnings and options research available for ADCT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, CH |
| Last close | 1.07 USD (-12.30%) |
| 52-week range | 0.939 USD – 1.44 USD |
| Trend regime | Range |
| 14-day RSI | 47 (Neutral) |
| Trailing P/E | -1.18 |
| Market cap | 0.15B |
| Dividend yield | 0.00% |
Available research for ADCT
Covered Call on ADCT: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ADCT: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ADCT: how it works, illustrative setup around the real 1.07 USD price, max profit/loss, breakeven and when to use it. Educational.
ADCT technical analysis: range, last 1.07 USD, RSI 47, 52w range 0.939 USD–1.44 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ADCT in?
ADC Therapeutics (ADCT) is classified under Healthcare (Biotechnology), listed on NYSE, CH.
Is ADCT in an uptrend or downtrend?
As of 2026-09-11, ADCT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ADCT's trailing P/E ratio?
ADCT's trailing P/E is -1.18, with a market cap of 0.15B. See the earnings research page for full valuation detail.